Kurse werden geladen...
Prognose
| Kaufen | 0 |
| Halten | 4 |
| Verkaufen | 0 |
Scoring-Modelle
| Dividenden-Strategie | 0 / 15 |
| HGI-Strategie | 13 / 18 |
| Levermann-Strategie | -5 / 13 |
News
SkinBioTherapeutics receives Croda boost
Shares in SkinBioTherapeutics PLC (AIM:SBTX) rose 6% after the company confirmed it had finalised terms with Croda PLC for the commercial launch of its SkinBiotix technology. The agreement includes royalties based on global sales of products developed using SkinBiotix.» Mehr auf proactiveinvestors.co.uk
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
NEW YORK , Aug. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hanger, Inc. (NYSE: HNGR)'s sale to Patient Square Capital for $18.75 in cash per share. If you are a Hanger shareholder, click here to learn more about your rights and options.» Mehr auf prnewswire.com
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates SBTX, IEA, PBFX, RMO
NEW YORK , Aug. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Silverback Therapeutics, Inc. (NASDAQ: SBTX) 's merger with ARS Pharmaceuticals, Inc. Under the terms of the merger agreement, assuming that Silverback's net cash at closing is $240 million, Silverback equity holders are expected to own approximately 37% of the combined company. If you are a Silverback shareholder, click here to learn more about your rights and options.» Mehr auf prnewswire.com
Unternehmenszahlen
| (EUR) | 2022 | |
|---|---|---|
| Umsatz | 0,00 | - |
| Bruttoeinkommen | 0,00 | - |
| Nettoeinkommen | −31,55 Mio | 59,95% |
| EBITDA | −33,11 Mio | 57,50% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 483,62 Mio€ |
Anzahl Aktien | 93,77 Mio |
52 Wochen-Hoch/Tief | 6,63€ - 2,46€ |
| Dividenden | Nein |
Beta | 0 |
KGV (PE Ratio) | 173,56 |
KGWV (PEG Ratio) | 1,50 |
KBV (PB Ratio) | 5,41 |
KUV (PS Ratio) | 15,76 |
Unternehmensprofil
Silverback Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen, das gewebebezogene Therapeutika für die Behandlung von chronischen Virusinfektionen, Krebs und anderen schweren Krankheiten entwickelt. Das Unternehmen bietet SBT8230 zur Behandlung chronischer Hepatitis-B-Virusinfektionen an, indem es eine antivirale Immunantwort durch gezielte TLR8-Aktivierung in der Leber auslöst. Silverback Therapeutics, Inc. wurde im Jahr 2016 gegründet und hat seinen Hauptsitz in Seattle, Washington.
| Name | SILVERBACK THERAP. -,0001 Aktie |
| CEO | Dr. Peter A. Thompson M.D. |
| Sitz | Seattle, wa USA |
| Website | |
| Industrie | Chemikalien |
| Börsengang | |
| Mitarbeiter | 90 |
Ticker Symbole
| Börse | Symbol |
|---|---|
NASDAQ | SBTX |
Assets entdecken
Shareholder von SILVERBACK THERAP. -,0001 Aktie investieren auch in folgende Assets
